

SCHERING PLOUGH CORP  
Form 8-K/A  
July 21, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K/A  
(Amendment No. 1)  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 21, 2008**

**SCHERING-PLOUGH CORPORATION**

(Exact Name of Registrant as Specified in its Charter)

New Jersey  
(State or Other Jurisdiction of  
Incorporation)

1-6571  
(Commission File Number)

22-1918501  
(IRS Employer  
Identification Number)

2000 Galloping Hill Road  
Kenilworth, NJ 07033

(Address of Principal Executive Office)

Registrant's telephone number, including area code: (908) 298-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**EXPLANATORY NOTE**

Schering-Plough is filing an amendment to its 8-K filed earlier today to furnish, as Exhibit 99.4., a press release issued by The University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit titled Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe. The exhibit was omitted from the 8-K filed earlier today due to technical difficulties.

**Item 9.01 Financial Statements and Exhibits**

*(d) Exhibits*

99.4 Press release dated July 21, 2008 titled Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.  
Schering-Plough Corporation

By: /s/ Steven H. Koehler  
Steven H. Koehler  
Vice President and Controller  
Date: July 21, 2008

---

Exhibit Index

Exhibit

Number Description

99.4 Press release dated July, 2008 titled Independent Analysis of the SEAS, SHARP and IMPROVE-IT studies of Ezetimibe